The ALS drug market is estimated at Billions of dollars for an effective drug which can stop or significantly slow disease progression. There are an estimated 120,000 ALS patients in the western world, and 450,000 patients worldwide. Patient cost per year in the US at late stages of the disease are estimated at $300,000 USD.
There are several companies at different stages of drug development for ALS, including: Cytokinetics, Biogen, AB Science, Brainstorm Cell Therapeutics, KadimaStem, Immunity Pharma, and Amylyx.
Disease Modifying vs. Symptomatic Treatment
Many of the available drugs and treatments in development today, treat merely the symptoms, and allow patients only a few extra months of functionality. NeuroSense’s drug aims to drastically slow or even halt disease progression, hence increasing patient’s life expectancy and improving quality of life.
Molecular Mechanisms vs. Stem Cells
In contrast to other companies which focus on stem cell treatment, aimed at affecting the system as a whole, NeuroSense emphasizes the underlying multifarious pathological and molecular mechanisms of the disease, in order to pinpoint the treatment effect.
Pain-Free vs. Invasive Treatment
Many of the treatments being developed for ALS patients are invasive, intrusive and include extraction and/or injection of cells or other infusions. NeuroSense’s drug comprises of a small, easy-to-use pill to be swallowed, therefore not impairing patient’s quality of life.